CN114026079A - 一种sglt2/dpp4抑制剂及其应用 - Google Patents

一种sglt2/dpp4抑制剂及其应用 Download PDF

Info

Publication number
CN114026079A
CN114026079A CN202080047668.5A CN202080047668A CN114026079A CN 114026079 A CN114026079 A CN 114026079A CN 202080047668 A CN202080047668 A CN 202080047668A CN 114026079 A CN114026079 A CN 114026079A
Authority
CN
China
Prior art keywords
compound
reaction
added
stirred
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080047668.5A
Other languages
English (en)
Other versions
CN114026079B (zh
Inventor
毛庆华
于涛
甘露
李翼
吴成德
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114026079A publication Critical patent/CN114026079A/zh
Application granted granted Critical
Publication of CN114026079B publication Critical patent/CN114026079B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

作为SGLT2/DPP4双抑制剂的一类化合物，以及在制备作为SGLT2/DPP4双抑制剂的药物中的应用。具体涉及式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202080047668.5A 2019-07-26 2020-07-24 一种sglt2/dpp4抑制剂及其应用 Active CN114026079B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910683099 2019-07-26
CN2019106830992 2019-07-26
CN202010119914 2020-02-26
CN2020101199145 2020-02-26
CN2020105722264 2020-06-22
CN202010572226 2020-06-22
PCT/CN2020/104521 WO2021018044A1 (zh) 2019-07-26 2020-07-24 一种sglt2/dpp4抑制剂及其应用

Publications (2)

Publication Number Publication Date
CN114026079A true CN114026079A (zh) 2022-02-08
CN114026079B CN114026079B (zh) 2022-10-18

Family

ID=74228349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080047668.5A Active CN114026079B (zh) 2019-07-26 2020-07-24 一种sglt2/dpp4抑制剂及其应用

Country Status (9)

Country Link
US (1) US20220242898A1 (zh)
EP (1) EP4006017B1 (zh)
JP (1) JP7227427B2 (zh)
KR (1) KR102471055B1 (zh)
CN (1) CN114026079B (zh)
AU (1) AU2020320890B2 (zh)
CA (1) CA3145678C (zh)
MX (1) MX2022001044A (zh)
WO (1) WO2021018044A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022160737A1 (zh) * 2021-01-26 2022-08-04 东宝紫星(杭州)生物医药有限公司 四氢吡喃环类化合物的晶型及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101343296A (zh) * 2007-07-10 2009-01-14 莱西肯医药有限公司 钠-葡萄糖协同转运蛋白2的抑制剂及其用法
WO2011070592A2 (en) * 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
CN102272136A (zh) * 2008-11-13 2011-12-07 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
CN104854096A (zh) * 2012-11-20 2015-08-19 莱西肯医药有限公司 钠葡萄糖协同转运蛋白1的抑制剂
CN105461762A (zh) * 2014-09-27 2016-04-06 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
WO2019134667A1 (zh) * 2018-01-05 2019-07-11 南京明德新药研发股份有限公司 一种SGLTs抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN104906582A (zh) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
MX2022001029A (es) * 2019-07-26 2022-05-24 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Inhibidor de sglts/dpp4 y aplicación del mismo.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101343296A (zh) * 2007-07-10 2009-01-14 莱西肯医药有限公司 钠-葡萄糖协同转运蛋白2的抑制剂及其用法
CN102272136A (zh) * 2008-11-13 2011-12-07 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
WO2011070592A2 (en) * 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
CN104854096A (zh) * 2012-11-20 2015-08-19 莱西肯医药有限公司 钠葡萄糖协同转运蛋白1的抑制剂
CN105461762A (zh) * 2014-09-27 2016-04-06 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
WO2019134667A1 (zh) * 2018-01-05 2019-07-11 南京明德新药研发股份有限公司 一种SGLTs抑制剂及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DARDI, T. KOUVATSOS等: "SGLT2 inhibitors", 《BIOCHEMICAL PHARMACOLOGY》 *

Also Published As

Publication number Publication date
JP7227427B2 (ja) 2023-02-21
US20220242898A1 (en) 2022-08-04
AU2020320890B2 (en) 2023-03-09
EP4006017A1 (en) 2022-06-01
KR20220031735A (ko) 2022-03-11
CA3145678A1 (en) 2021-02-04
WO2021018044A1 (zh) 2021-02-04
EP4006017A4 (en) 2023-09-06
AU2020320890A1 (en) 2022-03-17
JP2022533475A (ja) 2022-07-22
KR102471055B1 (ko) 2022-11-28
MX2022001044A (es) 2022-04-06
EP4006017B1 (en) 2024-10-23
CN114026079B (zh) 2022-10-18
CA3145678C (en) 2022-08-23

Similar Documents

Publication Publication Date Title
CN115698022B (zh) 五元杂芳并咪唑类化合物及其应用
CN115697338B (zh) 甲基取代的苯并二噁唑类化合物及其应用
CN114634510A (zh) 咪唑并吡啶衍生物及其用途
CN113227051B (zh) 用于视网膜疾病的化合物
JP7086075B2 (ja) Ｃｃｒ２／ｃｃｒ５受容体拮抗剤としてのビフェニル化合物
TW202317097A (zh) 戊二醯亞胺類化合物與其應用
CN114026079B (zh) 一种sglt2/dpp4抑制剂及其应用
JP7299408B2 (ja) ＳＧＬＴｓ／ＤＰＰ４阻害剤およびその使用
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN112218871B (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用
CN113439080A (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CN113825750B (zh) 作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN115003672A (zh) 喹啉并咪唑类化合物及其应用
KR100913495B1 (ko) 베타아미노기를 갖는 1,4-디아제펜 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
CN114728904A (zh) 用作选择性雄激素受体调节剂的双环类化合物
CN114746400A (zh) 用作选择性雄激素受体调节剂的化合物
CN118724796A (zh) 苯丙酸衍生物及其制备方法和应用
CN116789636A (zh) 双功能化合物及其制备方法、药物组合物和用途
CN116888099A (zh) 含β-胺基酮的短肽化合物及其应用
CN117136187A (zh) 新型抗乙肝化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062340

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant